October 09, 2015
1 min watch

VIDEO: Managing HIV in special populations

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN DIEGO — Anandi Sheth, MD, assistant professor of medicine at Emory University School of Medicine, summarizes four presentations from IDWeek 2015 that focused on HIV management in special populations.

Sheth mentions the WAVES study, which showed an improvement in viral outcomes among women who were treated with Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate, Gilead Sciences) vs. Norvir (ritonavir, AbbVie; RTV)-boosted Reyataz (atazanavir, Bristol-Myers Squibb) plus FTC/TDF. She also discusses HIV management among older adults, adolescents, substance users and those with psychiatric illnesses. 

Disclosures: Sheth reports no relevant financial disclosures.